MX364911B - Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. - Google Patents

Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.

Info

Publication number
MX364911B
MX364911B MX2015011243A MX2015011243A MX364911B MX 364911 B MX364911 B MX 364911B MX 2015011243 A MX2015011243 A MX 2015011243A MX 2015011243 A MX2015011243 A MX 2015011243A MX 364911 B MX364911 B MX 364911B
Authority
MX
Mexico
Prior art keywords
retinal
peptides
topical treatment
diabetic retinopathy
disesases
Prior art date
Application number
MX2015011243A
Other languages
English (en)
Other versions
MX2015011243A (es
Inventor
Canonge Rafael Simó
Pascual Cristina Hernández
Original Assignee
Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Hospital Univ Vall Dhebron Institut De Recerca filed Critical Fundacio Hospital Univ Vall Dhebron Institut De Recerca
Publication of MX2015011243A publication Critical patent/MX2015011243A/es
Publication of MX364911B publication Critical patent/MX364911B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un péptido análogo de GLP-1 con una longitud de secuencia de 13 a 50 aminoácidos, para usarse en el tratamiento tópico en el ojo y/o la prevención tópica ocular de una enfermedad neurodegenerativa retiniana, en donde dicho péptido comprende en la región del extremo N-terminal la secuencia que consiste de los aminoácidos: HXaa1 EGTFTSDXaa2SXaa3Xaa4(SEC ID NO: 1) en la cual: XAA1 es un aminoácido seleccionado de alanina y glicina; Xaa2 es un aminoácido seleccionado de valina y leucina; Xaa3 es un aminoácido seleccionado de serina y lisina; Xaa4 es un aminoácido seleccionado de tirosina y glutamina: e histidina es el residuo N-terminal.
MX2015011243A 2013-03-01 2014-02-27 Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. MX364911B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382063 2013-03-01
PCT/EP2014/053787 WO2014131815A1 (en) 2013-03-01 2014-02-27 Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role

Publications (2)

Publication Number Publication Date
MX2015011243A MX2015011243A (es) 2016-04-25
MX364911B true MX364911B (es) 2019-05-13

Family

ID=47901927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011243A MX364911B (es) 2013-03-01 2014-02-27 Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.

Country Status (14)

Country Link
US (1) US9707273B2 (es)
EP (1) EP2968471B1 (es)
JP (2) JP6368722B2 (es)
CN (1) CN105007931B (es)
CA (1) CA2901439C (es)
DK (1) DK2968471T3 (es)
ES (1) ES2644016T3 (es)
HR (1) HRP20171501T1 (es)
HU (1) HUE036542T2 (es)
MX (1) MX364911B (es)
PL (1) PL2968471T3 (es)
PT (1) PT2968471T (es)
SI (1) SI2968471T1 (es)
WO (1) WO2014131815A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907718A1 (en) 2013-04-23 2014-10-30 The Proctor & Gamble Company Hair consultation tool arrangement and method
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3393496T3 (pl) 2015-12-23 2024-04-22 The Johns Hopkins University Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
EP3397271B1 (en) 2015-12-30 2021-11-03 Marshall University Research Corporation Compositions and methods for treating retinopathy
BR112018072127A2 (pt) * 2016-04-29 2019-03-19 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
EP3443980A1 (en) * 2017-08-15 2019-02-20 Ciliocure Limited Compound for the treatment of patients with leptin-resistant obesity, bardet-biedl syndrome and other ciliopathies
US20230079395A1 (en) 2020-02-13 2023-03-16 Ferrer Internacional, S.A. Ophthalmic pharmaceutical composition and use thereof
GB202014740D0 (en) * 2020-09-18 2020-11-04 Invex Therapeutics Ltd Method of reducing intraocular pressure
US20220193201A1 (en) * 2020-10-19 2022-06-23 The Trustees Of The University Of Pennsylvania Glp-1r agonist reduces retinal inflammation and neuron death secondary to ocular hypertension
EP4248985A1 (en) 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptides for the treatment of retinitis pigmentosa

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
AU2003207961A1 (en) 2002-01-16 2003-07-30 Ramot At Tel Aviv University Ltd. Compositions and their use for enhancing and inhibiting fertilization
US20120021980A1 (en) * 2004-08-25 2012-01-26 Aegis Therapeutics, Inc. Compositions for drug administration
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2007062434A2 (en) 2005-11-22 2007-05-31 Crestwave Technologies (Pty) Ltd A mineral recovery process
US8362050B2 (en) * 2008-06-24 2013-01-29 Irm Llc Compounds and methods for modulating G protein-coupled receptors
EP2251028A1 (en) * 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
ES2362604B1 (es) 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用

Also Published As

Publication number Publication date
MX2015011243A (es) 2016-04-25
US20160000882A1 (en) 2016-01-07
CA2901439C (en) 2023-04-04
EP2968471A1 (en) 2016-01-20
CA2901439A1 (en) 2014-09-04
WO2014131815A1 (en) 2014-09-04
SI2968471T1 (sl) 2017-11-30
HRP20171501T1 (hr) 2017-11-17
CN105007931A (zh) 2015-10-28
HUE036542T2 (hu) 2018-07-30
BR112015020143A2 (pt) 2017-08-29
CN105007931B (zh) 2018-04-06
JP2016510728A (ja) 2016-04-11
ES2644016T3 (es) 2017-11-27
PT2968471T (pt) 2017-10-24
PL2968471T3 (pl) 2017-12-29
US9707273B2 (en) 2017-07-18
EP2968471B1 (en) 2017-07-19
JP6368722B2 (ja) 2018-08-01
DK2968471T3 (en) 2017-10-23
JP2018111702A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2015011243A (es) Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.
TN2010000298A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
NZ600732A (en) Oxyntomodulin peptide analogue
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
MY163100A (en) Short antimicrobial lipopeptides
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ708990A (en) Method for activating helper t cell
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension
MX2022002476A (es) Peptido q-er.
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
EA201391387A1 (ru) Нейропротекторные пептиды
MX2014008420A (es) Inhibidor de dipeptidil peptidasa-iv.
SG10201805039UA (en) Protease resistant peptides
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
CA2839298C (en) Anti-inflammatory pharmaceutical products
NZ736652A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.

Legal Events

Date Code Title Description
FG Grant or registration